Marinus Pharma finds the biotech imitation game can only last so long

first_img STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. It can pay to be a copycat — for a time.Consider Marinus Pharmaceuticals (MRNS), a little-known biotech that delivered the second-best stock performance in the sector last year. Why did Marinus enjoy an eightfold jump in its stock price in 2017? Because speculative investors viewed the company as a cheaper clone of high-flying Sage Therapeutics (SAGE). About the Author Reprints Adobe GET STARTED Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED What is it? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. Log In | Learn More center_img Marinus Pharma finds the biotech imitation game can only last so long Adam’s Take What’s included? Adam Feuerstein By Adam Feuerstein March 7, 2018 Reprints [email protected] @adamfeuerstein Tags biotechclinical trialsdrug developmentSTAT+last_img read more